Summary
The tolerance to and pharmacokinetics of intravenously administered penciclovir (BRL 39123A), a novel anti-herpes agent, were investigated in 15 healthy male subjects. The volunteers were divided into three groups, receiving either 10, 15 or 20 mg/kg penciclovir by a 60 min constant-rate infusion. Blood samples were taken sequentially up to 48 h after the start of the infusion and urine collections made at appropriate intervals up to 72 h. After a simple solid phase extraction, concentrations of penciclovir in plasma and urine were determined using HPLC with U. V detection.
Mean values of Cmax, corresponding usually with the end of infusion, and of AUC appeared to increase proportionately with dose. Furthermore, there was no evidence that dose significantly affected any individual pharmacokinetic parameter.
Penciclovir was distributed into tissues with an overall mean volume of distribution of approximately 1.51 · kg−1, i. e. approximately double that of body water. It was rapidly eliminated, with a mean total plasma clearance of 39.31 · h−1, and a mean terminal-phase half-life of 2.0 h. The majority of the dose, approximately 70%, was excreted unchanged in the urine. Mean renal clearance of BRL 39123 was 28.1 1 · h−1, which exceeds normal glomerular filtration rate and approaches renal plasma flow.
At all dose-levels, the infusions of penciclovir were well tolerated, with no evidence of drug-related adverse events.
Similar content being viewed by others
References
Boyd MR, Bacon TH, Sutton D, Cole M (1987) Antiherpesvirus Activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother31: 1238–1242
Boyd MR, Bacon TH, Sutton D (1988) Antiherpesvirus Activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother32:358–363
Vere Hodge TA, Perkins RM (1989) Mode of action of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) against Herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother33: 223–229
Fowles SE, Pierce DM, Prince WT, Staniforth D (1989) The pharmacokinetics of BL 39123A, a novel anti-herpes agent, administered by intravenous infusion to healthy subjects at doselevels of 10, 15 and 20 mg kg−1. Br J Clin Pharmacol28: 236P-237P
Fowles SE, Pierce DM (1989) HPLC method for the determination of BRL 39123 in human plasma and urine. Analyst114: 1373–1375
Allen GD (1990) MODFIT: a pharmacokinetics computer program. Biopharm Drug Dispos11: 477–498
Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
Remingtons Pharmaceuticals Sciences (1985) 17th edn. Mack Publishing Company, Euston, Pennsylvania
De Miranda P, Whitley RJ, Blum MR, Keeney RE, Barton N, Cocchetto DM, Good S, Hemstreet GP, Kirk LE, Page DA, Elion GB (1979) Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther 26:718–728
Laskin OL, De Miranda P, King DH, Page DA, Longstreth JA, Rocco L, Lietman PS (1982a) Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 21: 804–807
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fowled, S.E., Pierce, D.M., Prince, W.T. et al. The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur J Clin Pharmacol 43, 513–516 (1992). https://doi.org/10.1007/BF02285093
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02285093